Want to see JP:6523 full AI Analyst Report?
Top Page
PHC Holdings Corp.
(6523)
Select Model
Select Model
Rating:47Neutral
Price Target:
¥1,043.00
▼(-6.21% Downside)
Action:Reiterated
Date:05/15/26
The score is held down primarily by unstable earnings (near break-even in 2026 after a strong 2025) and still-elevated leverage despite improvement, with technical indicators also bearish as the price sits below key moving averages and momentum gauges are negative. Positive and improving free cash flow and a ~4.23% dividend yield provide partial support, but the very high P/E (279.9) keeps the valuation component weak.
Positive Factors
Revenue growth acceleration
A sustained step-up to +12.9% revenue growth signals strengthening end-market demand and improving product mix across diagnostics, life‑science and medical equipment. This revenue momentum supports scale, broadens installed bases and underpins longer‑term cash flow and reinvestment capacity.
Negative Factors
Profitability volatility
Large swings from multi‑year losses to a one‑year profit and back toward break‑even indicate unstable operating performance. This volatility complicates long‑range planning, weakens returns on invested capital, and raises execution risk for sustaining margins and funding reinvestment without recurring earnings consistency.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue growth acceleration
A sustained step-up to +12.9% revenue growth signals strengthening end-market demand and improving product mix across diagnostics, life‑science and medical equipment. This revenue momentum supports scale, broadens installed bases and underpins longer‑term cash flow and reinvestment capacity.
Read all positive factors
PHC Holdings Corp. (6523) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥133.81B
Dividend Yield3.73%
Average Volume (3M)164.09K
Price to Earnings (P/E)273.0
Beta (1Y)0.52
Revenue Growth0.78%
EPS Growth-95.37%
CountryJP
Employees9,245
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)3.85
Shares Outstanding127,319,580
10 Day Avg. Volume194,380
30 Day Avg. Volume164,093
Financial Highlights & Ratios
PEG Ratio-2.94
Price to Book (P/B)0.85
Price to Sales (P/S)0.38
P/FCF Ratio4.13
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)125.22
Revenue Forecast (FY)¥366.92B
PHC Holdings Corp. Business Overview & Revenue Model
Company Description
PHC Holdings Corporation, through its network of subsidiaries, specializes in the innovation, production, and sale of medical instruments, advanced healthcare technology solutions, and life science merchandise. The company's product line includes ...
How the Company Makes Money
PHC Holdings primarily generates revenue by selling healthcare products and related services through three major business areas. (1) Diagnostics: the company sells in-vitro diagnostic instruments (e.g., clinical analyzers and point-of-care devices...
PHC Holdings Corp. Financial Statement Overview
Summary
Income Statement
44
Neutral
Balance Sheet
41
Neutral
Cash Flow
63
Positive
| Breakdown | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 364.40B | 361.59B | 353.90B | 356.43B | 340.45B |
| Gross Profit | 165.26B | 166.22B | 157.97B | 169.13B | 165.24B |
| EBITDA | 47.72B | 52.33B | 30.15B | 36.76B | 37.56B |
| Net Income | 492.00M | 10.48B | -12.89B | -3.22B | -8.46B |
Balance Sheet | |||||
| Total Assets | 542.51B | 532.48B | 564.33B | 561.57B | 591.32B |
| Cash, Cash Equivalents and Short-Term Investments | 39.82B | 43.90B | 51.82B | 63.25B | 97.63B |
| Total Debt | 234.56B | 269.26B | 300.28B | 307.24B | 323.32B |
| Total Liabilities | 381.63B | 391.31B | 425.16B | 422.74B | 455.25B |
| Stockholders Equity | 161.67B | 141.64B | 139.51B | 138.01B | 135.37B |
Cash Flow | |||||
| Free Cash Flow | 33.37B | 30.33B | 26.67B | 9.86B | 39.32B |
| Operating Cash Flow | 42.46B | 41.94B | 41.30B | 21.38B | 51.05B |
| Investing Cash Flow | -8.45B | -8.47B | -23.68B | -17.52B | -12.52B |
| Financing Cash Flow | -39.82B | -39.07B | -36.53B | -40.83B | -7.01B |
PHC Holdings Corp. Technical Analysis
Positive
1112.00
Price Trends
1040.02
Positive
1042.92
Positive
1038.98
Positive
Market Momentum
-1.18
Negative
52.64
Neutral
71.72
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:6523, the sentiment is Positive. The current price of 1112 is above the 20-day moving average (MA) of 1035.70, above the 50-day MA of 1040.02, and above the 200-day MA of 1038.98, indicating a bullish trend. The MACD of -1.18 indicates Negative momentum. The RSI at 52.64 is Neutral, neither overbought nor oversold. The STOCH value of 71.72 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:6523.
PHC Holdings Corp. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
78 Outperform | ¥17.67B | 13.35 | ― | 3.02% | 13.43% | 7.14% | |
67 Neutral | ¥9.09B | 11.82 | ― | 1.89% | 6.09% | -6.33% | |
61 Neutral | ¥245.83B | 16.80 | ― | 1.92% | 4.29% | 3.92% | |
56 Neutral | ¥83.48B | 22.50 | ― | 2.31% | 3.35% | 74.41% | |
54 Neutral | ¥24.86B | 94.59 | ― | 3.12% | -4.77% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | ¥133.81B | 272.99 | 2.42% | 3.73% | 0.78% | -95.37% |
* Healthcare Sector Average
JP:6523
PHC Holdings Corp.
1,051.00
174.54
19.91%
JP:4549
Eiken Chemical Co., Ltd.
2,532.00
546.67
27.54%
JP:6678
Techno Medica Co., Ltd.
2,073.00
278.45
15.52%
JP:6849
Nihon Kohden Corporation
1,499.50
-119.90
-7.40%
JP:7600
Japan Medical Dynamic Marketing, Inc.
944.00
398.50
73.05%
JP:7963
Koken Ltd.
1,848.00
158.37
9.37%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.